# ZYMEWORKS INC. (ZYME) · Edgar & Edgarette company card

> Zymeworks (ZYME) grew revenue 38.9% in FY2025 to $106 million, operating margin -87.3% against a -3.8% median for pharmaceutical preparations, equity 77.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1937653 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ZYME) · [JSON](https://www.pops4.com/boards/company/ZYME.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $106M |
| Revenue growth, 1 year | 38.9% |
| Revenue growth per year | 41.2% |
| Operating margin | -87.3% (prior year -179.7%) |
| Net margin | -76.6% |
| Operating cash flow | −$33M |
| Capital spending | $2M |
| Free cash flow | −$35M |
| Cash | $41M |
| Long-term debt | — |
| Total assets | $347M |
| Total equity | $269M |
| Equity ÷ assets | 77.5% |
| Return on equity | -30.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3.24 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Old boat · three warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -87.3% in FY2025
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $106.0M (FY2025). Experience: revenue up 38.9% on the year, up 41.2% a year over 4 years; operating margin -87.3%, up from -179.7%. Soundness: equity 77.5% of assets, return on equity -30.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $83.0M and $133.5M next year (method v4.1: its own 2-year record of growth weighed at 25% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $73.6M to $151.3M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -87.3% against a -3.8% median; growth 38.9% against 13.7%.

Range logged 2026-09-24, receipt 1e71ac1caf08ef64, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/1937653/000119312526135610/0001193125-26-135610-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-26 · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000119312526431936/0001193125-26-431936-index.htm)
- 8-K · filed 2026-10-23 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/0001937653-26-000055-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/0001193125-26-399383-index.htm)
- 8-K · filed 2026-08-25 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/0001937653-26-000051-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/0001937653-26-000047-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/0001937653-26-000046-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001937653.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1937653

## Cite

POPS4, Edgar & Edgarette: ZYMEWORKS INC. (ZYME) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/ZYME. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.